Zonisamide (sodium)

Zonisamide (sodium)产品描述：Zonisamide sodium is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug. Target: Calcium channel inhibitor; Sodium channel inhibitor Zonisamide sodium is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures for adults; infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, myoclonic, and generalized tonic clonic seizure. Zonisamide sodium is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug. It has shown activity in various animal models of epilepsy, and although a detailed mode of action awaits clarification it appears to block the propagation/spread of seizure discharges and to suppress the epileptogenic focus [1]. Zonisamide sodium 500 mg/day was significantly superior to placebo in reducing the frequency of complex partial seizures (-51% versus -16%), all partial seizures and all seizures, with dose-dependent benefit provided over a 100-500 mg/day dose range. Supporting trials have confirmed significant increases in reduction in median seizure frequency (up to 41%) and responder rates (35-42%) compared with placebo following zonisamide sodium 400-600 mg/day, enabling 20-27% of patients to attain >or=75% reduction in seizure frequency [2]. Clinical indications: Epilepsy; Lewy body dementia; Parkinsons disease Toxicity: Anorexia; Somnolence; Dizziness; Irritability; Confusional state; Depression; Diplopia; Memory impairment


公司介绍：MedChemExpress(MCE)专注于各种YZ剂、激动剂、API及化合物库，总部位于美国新泽西，分别在瑞典和上海设有欧洲区子公司和亚洲区总代理，营销网点遍及20多个国家地区。MCE经过多年努力已成为生物活性小分子领域的供应商， 产品涵盖癌症、神经科学、抗感染、表观遗传学等20个热门研究领域，PI3K、MAPK等近千个细分靶点，超过4000个活性小分子化合物现货，以及GPCR、API、离子通道等超过20种不同类型的化合物库，同时提供从毫克到千克的专业定制合成服务。
MCE 对每批产品都进行严格的LCMS和NMR检验，其产品已被近万名客户广泛使用并发表大量文章、专利；
MCE 定期增加各领域热门YZ剂、激动剂，不断扩增已有化合物库，以满足的科研需求；
数千种产品在上海有充足备货，24-48小时内送达客户；
大量产品提供免费SY装； 已为多个知名企业、院校构建各种定制型化合物库。

产品链接：www.medchemexpress.cn/zonisamide-sodium.html